section name header

Indications ⬇

BEERS REMS

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: bradycardia, heart block

Endo: gynecomastia

Hemat: BLEEDING

Resp: dyspnea, central sleep apnea, Cheyne-Stokes respiration

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANGIOEDEMA)

Interactions ⬆ ⬇

Drug-drug:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

Acute Coronary Syndrome or History of Myocardial Infarction

Coronary Artery Disease Without a History of Myocardial Infarction or Stroke

Acute Ischemic Stroke or Transient Ischemic Attack

US Brand Names ⬆ ⬇

Brilinta

Action ⬆ ⬇

  • Both parent drug and its active metabolite inhibit platelet aggregation by reversibly interacting with platelet P2Y12ADP-receptors, preventing signal transduction and platelet activation.
Therapeutic effects:
  • Reduction in risk of cardiovascular death, MI, and stroke associated with ACS.
  • Reduction in stent thrombosis.
  • Reduction in risk of first MI or stroke in high-risk patients with coronary artery disease.
  • Reduction in risk of stroke in patients with acute ischemic stroke or TIA.

Classifications ⬆ ⬇

Therapeutic Classification: antiplatelet agents

Pharmacologic Classification: platelet aggregation inhibitors

Pharmacokinetics ⬆ ⬇

Absorption: 36% absorbed following oral administration.

Distribution: Well distributed to tissues.

Protein Binding: 99%.

Metabolism/Excretion: Mostly metabolized in the liver by the CYP3A4 isoenzyme, with some metabolism by the CYP3A5 isoenzyme) with conversion to an active metabolite (AR-C124910XX); excretion primarily via biliary secretion; <1% excreted unchanged or as active metabolite in urine.

Half-Life: Ticagrelor: 7 hr; Active metabolite: 9 hr.

Time/Action Profile ⬆ ⬇

(inhibition of platelet aggregation)

ROUTEONSETPEAKDURATION
POwithin 30 min4 hr5 days‡

‡Following discontinuation.

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

TYE-ka-GREL-or

Code ⬆

NDC Code